Stock Research: Cara Therapeutics

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Cara Therapeutics

NasdaqGM:CARA US1407551092
64
  • Value
    100
  • Growth
    83
  • Safety
    Safety
    8
  • Combined
    85
  • Sentiment
    29
  • 360° View
    360° View
    64
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven and cancer cells. It operates in the biopharmaceutical industry with a focus on fibrosis-driven diseases (idiopathic pulmonary fibrosis, hepatocellular carcinoma) and cancer. The regions of operation are not specified in the description. In the last fiscal year, the company had a market cap of $234 million, profits of $7 million, revenue of $7 million, and 10 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 64 (better than 64% compared with alternatives), overall professional sentiment and financial characteristics for the stock Cara Therapeutics are above average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Cara Therapeutics. The consolidated Growth Rank has a good rank of 83, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 83% of competitors in the same industry. In addition, the consolidated Safety Rank has a safer rank of 100 which means that the company has a financing structure that is safer than 100% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the consolidated Value Rank has a less desirable rank of 8 which means that the share price of Cara Therapeutics is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is higher than for 92% of alternative stocks in the same industry. The consolidated Sentiment Rank also has a low rank of 29, which means that professional investors are more pessimistic about the stock than for 71% of alternative investment opportunities. ...read more

more
Index
NASDAQ
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Growth
Shows a company's growth potential.
High Growth Tough Times
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
8 54 63 33
Growth
83 13 1 31
Safety
Safety
100 100 83 83
Sentiment
29 20 37 77
360° View
360° View
64 64 21 55
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
91 5 64 3
Opinions Change
70 50 50 72
Pro Holdings
n/a 12 12 99
Market Pulse
4 11 57 48
Sentiment
29 20 37 77
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
8 54 63 33
Growth
83 13 1 31
Safety Safety
100 100 83 83
Combined
85 85 18 18
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
72 72 72 30
Price vs. Earnings (P/E)
1 20 34 33
Price vs. Book (P/B)
10 95 89 50
Dividend Yield
1 1 1 1
Value
8 54 63 33
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
1 12 4 95
Profit Growth
86 76 23 1
Capital Growth
100 14 3 31
Stock Returns
89 23 3 37
Growth
83 13 1 31
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
68 100 100 100
Refinancing
47 96 99 47
Liquidity
1 1 29 29
Safety Safety
100 100 83 83

Similar Stocks

Discover high‑ranked alternatives to Cara Therapeutics and broaden your portfolio horizons.

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Alphabet

NasdaqGS:GOOG.L
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Lithia Motors

NYSE:LAD
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.